CY1106813T1 - Χρηση αναστολεων του συστηματος ρενινης-αγγειοτενσινης - Google Patents
Χρηση αναστολεων του συστηματος ρενινης-αγγειοτενσινηςInfo
- Publication number
- CY1106813T1 CY1106813T1 CY20071101077T CY071101077T CY1106813T1 CY 1106813 T1 CY1106813 T1 CY 1106813T1 CY 20071101077 T CY20071101077 T CY 20071101077T CY 071101077 T CY071101077 T CY 071101077T CY 1106813 T1 CY1106813 T1 CY 1106813T1
- Authority
- CY
- Cyprus
- Prior art keywords
- renin
- angiotensin system
- system inhibitors
- trandolapril
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000036454 renin-angiotensin system Effects 0.000 title abstract 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 2
- 229960002051 trandolapril Drugs 0.000 abstract 2
- QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 abstract 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 abstract 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 abstract 1
- 239000002083 C09CA01 - Losartan Substances 0.000 abstract 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 abstract 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 abstract 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 1
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 abstract 1
- 108010061435 Enalapril Proteins 0.000 abstract 1
- 108010007859 Lisinopril Proteins 0.000 abstract 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 abstract 1
- 229960004530 benazepril Drugs 0.000 abstract 1
- 229960000932 candesartan Drugs 0.000 abstract 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 abstract 1
- 229960000830 captopril Drugs 0.000 abstract 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
- 229950005749 ceronapril Drugs 0.000 abstract 1
- 229960005025 cilazapril Drugs 0.000 abstract 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 abstract 1
- 229960005227 delapril Drugs 0.000 abstract 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000873 enalapril Drugs 0.000 abstract 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 abstract 1
- 229960004563 eprosartan Drugs 0.000 abstract 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 abstract 1
- 229960002490 fosinopril Drugs 0.000 abstract 1
- 229960001195 imidapril Drugs 0.000 abstract 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 abstract 1
- 229960002198 irbesartan Drugs 0.000 abstract 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
- 229960002394 lisinopril Drugs 0.000 abstract 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 abstract 1
- 229960004773 losartan Drugs 0.000 abstract 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 abstract 1
- 229960005170 moexipril Drugs 0.000 abstract 1
- 229950006549 moveltipril Drugs 0.000 abstract 1
- 229960002582 perindopril Drugs 0.000 abstract 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960001455 quinapril Drugs 0.000 abstract 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical group C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 abstract 1
- 229960003401 ramipril Drugs 0.000 abstract 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 abstract 1
- 229960002909 spirapril Drugs 0.000 abstract 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 abstract 1
- 108700035424 spirapril Proteins 0.000 abstract 1
- 229960000651 tasosartan Drugs 0.000 abstract 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 abstract 1
- 229960005187 telmisartan Drugs 0.000 abstract 1
- 229960004084 temocapril Drugs 0.000 abstract 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
- C08G61/02—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes
- C08G61/04—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms
- C08G61/06—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds
- C08G61/08—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Χρησιμοποιείται αναστολέας του συστήματος ρενίνης-αγγειοτενσίνης για την παρασκευή φαρμάκου για την θεραπευτική αγωγή ή πρόληψη εγκεφαλικού επεισοδίου ή της υποτροπής του. Ο αναστολέας επιλέγεται από κιναπρίλη, καπτοπρίλη, λισινοπρίλη, περινδοπρίλη, τρανδολαπρίλη, εναλαπρίλη, μοεξιπρίλη, φοσινοπρίλη, ραμιπρίλη, σιλαζαπρίλη, ιμιδαπρίλη, σπιραπρίλη, τεμοκαπρίλη, βεναζεπρίλη, αλακεπρίλη, κεροναπρίλη, δελαπρίλη, μοβελτιπρίλη, τρανδολαπρίλη, λοσαρτάνη, βαλσαρτάνη, ιρβεσαρτάνη, κανδεσαρτάνη, επροσαρτάνη, τασοσαρτάνη και τελμισαρτάνη.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9722026.3A GB9722026D0 (en) | 1997-10-17 | 1997-10-17 | Use of compounds |
GBGB9810855.8A GB9810855D0 (en) | 1998-05-20 | 1998-05-20 | Use of compounds |
EP98947698A EP1023067B2 (en) | 1997-10-17 | 1998-10-19 | The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106813T1 true CY1106813T1 (el) | 2012-05-23 |
Family
ID=26312447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101077T CY1106813T1 (el) | 1997-10-17 | 2007-08-09 | Χρηση αναστολεων του συστηματος ρενινης-αγγειοτενσινης |
Country Status (19)
Country | Link |
---|---|
US (7) | US7071183B2 (el) |
EP (4) | EP1559424A3 (el) |
JP (2) | JP5187991B2 (el) |
KR (3) | KR100572080B1 (el) |
CN (1) | CN1123342C (el) |
AP (1) | AP1300A (el) |
AT (2) | ATE294579T1 (el) |
AU (1) | AU742506B2 (el) |
CA (2) | CA2306216C (el) |
CY (1) | CY1106813T1 (el) |
DE (2) | DE69830069T3 (el) |
DK (2) | DK1498124T3 (el) |
ES (2) | ES2238770T5 (el) |
HU (2) | HU0900792D0 (el) |
NO (1) | NO326231B1 (el) |
PL (2) | PL197164B1 (el) |
PT (2) | PT1023067E (el) |
UY (2) | UY25972A1 (el) |
WO (1) | WO1999020260A2 (el) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
DE60022525T2 (de) * | 1999-08-30 | 2006-06-14 | Sanofi Aventis Deutschland | Ramipril zur vorbeugung von kardiovaskulären vorfällen |
EA005310B1 (ru) * | 2000-04-10 | 2004-12-30 | Юити Исида | Гипотензивные средства |
WO2002099098A1 (en) * | 2001-04-04 | 2002-12-12 | American Diagnostica, Inc | Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof |
GB0119460D0 (en) | 2001-08-09 | 2001-10-03 | Ark Therapeutics Ltd | The use of inhibitors of the renin-angiotensin system |
WO2003043615A2 (de) * | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertoniebehandlung während der akuten phase des schlaganfalls |
EP1382334A1 (en) * | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
US7470519B2 (en) | 2002-08-29 | 2008-12-30 | American Diagnostica, Inc. | Methods for detecting TAFIa or TAFIai |
EP1600166A4 (en) * | 2003-01-17 | 2008-02-27 | Takeda Pharmaceutical | SKELETAL MUSCLE PROTECTIVE AGENT |
WO2005084648A1 (en) * | 2004-02-27 | 2005-09-15 | Ranbaxy Laboratories Limited | Pharmaceutical compositions comprising candesartan cilexetil |
ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
WO2006009325A1 (ja) * | 2004-07-23 | 2006-01-26 | Ono Pharmaceutical Co., Ltd. | メタロプロテアーゼ阻害剤 |
EP2374508A1 (en) * | 2005-03-21 | 2011-10-12 | Vicus Therapeutics SPE 1, LLC | Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia |
AR068814A1 (es) * | 2007-08-29 | 2009-12-09 | Orion Corp | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
CA2699854A1 (en) * | 2007-09-17 | 2009-03-26 | Bioneris Ab | Use of compounds comprising phosphorous for the treatment of cachexia |
US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
WO2012135597A2 (en) | 2011-03-30 | 2012-10-04 | The Johns Hopkins University | Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair |
KR20130074808A (ko) * | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
EP2832357A1 (en) | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
WO2015108342A1 (ko) * | 2014-01-14 | 2015-07-23 | 최원철 | 루테리알의 형태특성을 이용한 암 예방제 또는 항암제의 스크리닝 방법 |
JP2016183174A (ja) * | 2016-05-12 | 2016-10-20 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 双極性トランスカロテノイド塩及びそれらの使用 |
US11081240B2 (en) | 2018-06-14 | 2021-08-03 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition |
DE202023100085U1 (de) | 2023-01-09 | 2023-02-03 | Sundararajan Gothandam | Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2655989B1 (fr) * | 1989-12-20 | 1992-02-28 | Adir | Nouveaux derives d'amino-acides substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5049553A (en) * | 1990-01-04 | 1991-09-17 | E. R. Squibb & Sons, Inc. | Method for preventing or treating symptoms resulting from closed head injuries employing an ace inhibitor |
GB2241890A (en) | 1990-03-12 | 1991-09-18 | Squibb & Sons Inc | Preventing onset of or treating protein catabolism using an ace inhibitor |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
CA2048699A1 (en) * | 1990-09-04 | 1992-03-05 | Abraham Sudilovsky | Method for preventing or treating cerebro-vascular disease employing ceronapril |
CA2052014A1 (en) | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
TW197945B (el) * | 1990-11-27 | 1993-01-11 | Hoechst Ag | |
FI905896A (fi) * | 1990-11-29 | 1992-05-30 | Valmet Paper Machinery Inc | Formningsgapsarrangemang i en dubbelviraformare av en pappersmaskin. |
GB9027199D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5591762A (en) * | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
GB9108811D0 (en) * | 1991-04-24 | 1991-06-12 | Erba Carlo Spa | N-imidazolyl derivatives of substituted indole |
EP0670737A4 (en) | 1992-03-26 | 1996-05-29 | Gensia Inc | IN VIVO PEPTIDE THERAPY. |
US5972990A (en) | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US5374643A (en) | 1992-09-11 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Aryl urea (thiourea) and cyanoguanidine derivatives |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5824696A (en) * | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
US5464854A (en) * | 1993-11-11 | 1995-11-07 | Depadova; Anathony S. | Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. |
CA2140722A1 (en) * | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
US5550118A (en) * | 1994-01-31 | 1996-08-27 | Eli Lilly And Company | Polyhydronorharman synthase inhibitors |
US5468757A (en) * | 1994-01-31 | 1995-11-21 | Eli Lilly And Company | 6-azaindole thromboxane synthase inhibitors |
DE4410997A1 (de) * | 1994-03-30 | 1995-10-26 | Isis Pharma Gmbh | Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen |
DE4420102A1 (de) | 1994-06-09 | 1995-12-14 | Asta Medica Ag | Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5538991A (en) | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
US5645839A (en) * | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
TW356468B (en) * | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
DK0853477T3 (da) * | 1995-10-06 | 2003-02-10 | Novartis Ag | AT1-receptor-antagonister til forebyggelse og behandling af postiskæmisk nyresvigt og til beskyttelse af iskæmiske nyrer |
EP0868179A4 (en) * | 1995-12-12 | 2002-01-30 | Merck & Co Inc | NEW USE OF LOSARTAN |
US6258032B1 (en) * | 1997-01-29 | 2001-07-10 | William M. Hammesfahr | Method of diagnosis and treatment and related compositions and apparatus |
US6420412B2 (en) * | 1996-03-29 | 2002-07-16 | Smithkline Beecham Corporation | Eprosartan dihydate and a process for its production and formulation |
DE19614533A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung |
DE19614542A1 (de) * | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
US20040122096A1 (en) * | 1996-06-03 | 2004-06-24 | Hoechst Aktiengesellschaft | Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids |
DE19636046A1 (de) * | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
KR20000035992A (ko) | 1996-09-10 | 2000-06-26 | 메디녹스, 인크. | 폴리디티오카르바메이트 함유 거대분자 및 치료 및 진단을 위한 |
US6008221A (en) | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
PL334014A1 (en) * | 1996-12-18 | 2000-01-31 | Basf Ag | Heterocyclic derivatives of carboxylic acids, their preduction and application as antagonists of endothelin receptors |
EP0855392A3 (de) | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
US6197505B1 (en) * | 1997-04-04 | 2001-03-06 | Pyrosequencing Ab | Methods for assessing cardiovascular status and compositions for use thereof |
US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
DE60022525T2 (de) * | 1999-08-30 | 2006-06-14 | Sanofi Aventis Deutschland | Ramipril zur vorbeugung von kardiovaskulären vorfällen |
-
1998
- 1998-10-19 PL PL377096A patent/PL197164B1/pl unknown
- 1998-10-19 WO PCT/GB1998/003122 patent/WO1999020260A2/en active IP Right Grant
- 1998-10-19 DK DK04021889T patent/DK1498124T3/da active
- 1998-10-19 HU HU0900792A patent/HU0900792D0/hu not_active Application Discontinuation
- 1998-10-19 CN CN98811314A patent/CN1123342C/zh not_active Expired - Fee Related
- 1998-10-19 AT AT98947698T patent/ATE294579T1/de active
- 1998-10-19 JP JP2000516658A patent/JP5187991B2/ja not_active Expired - Fee Related
- 1998-10-19 KR KR1020057013064A patent/KR100572080B1/ko active IP Right Review Request
- 1998-10-19 HU HU0003982A patent/HUP0003982A3/hu unknown
- 1998-10-19 KR KR1020007004104A patent/KR20010031177A/ko active Search and Examination
- 1998-10-19 PL PL340838A patent/PL193215B1/pl not_active IP Right Cessation
- 1998-10-19 KR KR10-2000-7004109A patent/KR100523112B1/ko not_active IP Right Cessation
- 1998-10-19 AT AT04021889T patent/ATE366110T1/de active
- 1998-10-19 ES ES98947698T patent/ES2238770T5/es not_active Expired - Lifetime
- 1998-10-19 AU AU94533/98A patent/AU742506B2/en not_active Ceased
- 1998-10-19 AP APAP/P/2000/001796A patent/AP1300A/en active
- 1998-10-19 PT PT98947698T patent/PT1023067E/pt unknown
- 1998-10-19 DE DE69830069T patent/DE69830069T3/de not_active Expired - Lifetime
- 1998-10-19 PT PT04021889T patent/PT1498124E/pt unknown
- 1998-10-19 EP EP05009398A patent/EP1559424A3/en not_active Withdrawn
- 1998-10-19 ES ES04021889T patent/ES2287617T3/es not_active Expired - Lifetime
- 1998-10-19 EP EP04021889A patent/EP1498124B1/en not_active Revoked
- 1998-10-19 CA CA2306216A patent/CA2306216C/en not_active Expired - Fee Related
- 1998-10-19 CA CA2677910A patent/CA2677910C/en not_active Expired - Lifetime
- 1998-10-19 DE DE69838042T patent/DE69838042T2/de not_active Expired - Lifetime
- 1998-10-19 EP EP98947698A patent/EP1023067B2/en not_active Expired - Lifetime
- 1998-10-19 EP EP20070102160 patent/EP1776954A3/en not_active Ceased
- 1998-10-19 DK DK98947698.1T patent/DK1023067T4/da active
-
2000
- 2000-01-17 UY UY25972A patent/UY25972A1/es not_active Application Discontinuation
- 2000-01-17 UY UY25971A patent/UY25971A1/es not_active IP Right Cessation
- 2000-04-14 NO NO20001979A patent/NO326231B1/no not_active IP Right Cessation
-
2002
- 2002-07-26 US US10/206,659 patent/US7071183B2/en not_active Expired - Fee Related
-
2005
- 2005-04-29 US US11/119,181 patent/US7998953B2/en not_active Expired - Fee Related
- 2005-04-29 US US11/118,824 patent/US20050192326A1/en not_active Abandoned
-
2006
- 2006-05-25 US US11/441,648 patent/US8003679B2/en not_active Expired - Fee Related
-
2007
- 2007-08-09 CY CY20071101077T patent/CY1106813T1/el unknown
-
2008
- 2008-09-05 US US12/205,090 patent/US20090069348A1/en not_active Abandoned
-
2009
- 2009-07-15 JP JP2009166483A patent/JP2009242426A/ja active Pending
-
2012
- 2012-01-30 US US13/360,895 patent/US8604070B2/en not_active Expired - Fee Related
-
2013
- 2013-10-21 US US14/058,689 patent/US20140045907A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106813T1 (el) | Χρηση αναστολεων του συστηματος ρενινης-αγγειοτενσινης | |
PE20020229A1 (es) | COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE | |
JP2003521437A5 (el) | ||
NZ701609A (en) | Liquid formulation comprising propylene glycol and an inodilator | |
HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
CA2332608A1 (en) | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination | |
RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
JP2003527325A5 (el) | ||
ATE303800T1 (de) | Ramipril zur vorbeugung von kardiovaskulären vorfällen | |
IL160643A (en) | Orally administrable pharmaceutical dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor and aspirin and a packaged kit | |
AR079428A1 (es) | Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares | |
RU2002107985A (ru) | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений | |
JP2018507244A5 (el) | ||
IS8332A (is) | Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma | |
JP2016053057A5 (el) | ||
EP1578414A4 (en) | PHENYLALANINE DERIVATIVES ALSDIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
EP1638950A4 (en) | CYCLOHEXYLGLYCIN DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES | |
WO2008028965A3 (en) | Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof | |
WO2005011586A3 (en) | Treatment and preventi0n of cardiovascular events | |
RU2006135205A (ru) | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда | |
JP2013506684A5 (el) | ||
AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
RU2001122113A (ru) | Применение антагонистов рецептора ангиотензина II для лечения острого инфаркта миокарда | |
AR068814A1 (es) | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso | |
AU2003275304A1 (en) | Use of caspase inhibitors as therapeutic agent against radiation-induced injury |